↓ Skip to main content

Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells

Overview of attention for article published in BMC Cancer, November 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter
1 tweeter
patent
1 patent

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells
Published in
BMC Cancer, November 2011
DOI 10.1186/1471-2407-11-470
Pubmed ID
Authors

David J Taylor, Christine E Parsons, Haiyong Han, Arul Jayaraman, Kaushal Rege

Abstract

Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) and agonistic antibodies to death receptor 4 and 5 are promising candidates for cancer therapy due to their ability to induce apoptosis selectively in a variety of human cancer cells, while demonstrating little cytotoxicity in normal cells. Although TRAIL and agonistic antibodies to DR4 and DR5 are considered safe and promising candidates in cancer therapy, many malignant cells are resistant to DR-mediated, TRAIL-induced apoptosis. In the current work, we screened a small library of fifty-five FDA and foreign-approved anti-neoplastic drugs in order to identify candidates that sensitized resistant prostate and pancreatic cancer cells to TRAIL-induced apoptosis.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Sweden 1 2%
United Kingdom 1 2%
United States 1 2%
Poland 1 2%
Unknown 45 90%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 28%
Student > Ph. D. Student 10 20%
Student > Master 6 12%
Professor > Associate Professor 4 8%
Student > Doctoral Student 3 6%
Other 6 12%
Unknown 7 14%
Readers by discipline Count As %
Agricultural and Biological Sciences 14 28%
Biochemistry, Genetics and Molecular Biology 9 18%
Medicine and Dentistry 7 14%
Chemistry 5 10%
Computer Science 2 4%
Other 3 6%
Unknown 10 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 February 2021.
All research outputs
#5,636,197
of 20,185,820 outputs
Outputs from BMC Cancer
#1,392
of 7,229 outputs
Outputs of similar age
#36,648
of 131,139 outputs
Outputs of similar age from BMC Cancer
#63
of 292 outputs
Altmetric has tracked 20,185,820 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 7,229 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 131,139 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 292 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.